Relationship between UGT1A16/28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy

A retrospective study was performed to analyze the relationship between uridine diphosphate glucuronosyltransferase 1A1 ( ) / gene polymorphisms and adverse reactions associated with irinotecan (CPT-11)-based chemotherapy. The correlation between polymorphisms and the clinical efficacy of CPT-11 was also analyzed, along with the influence of age and tumor type. Patients administered a CPT-11-based regimen in the Beijing Cancer Hospital from April 2015 to September 2016 were included in our study (n=81). Blood samples for detecting were collected from each patient after various administration regimens. Colorectal cancer patients with the mutant genotype had a significantly higher risk of severe delayed diarrhea than that of wild-type individuals when administered a CPT-11 dose ≥130 mg/m ( =0.042); the same phenomenon was observed when the and mutant genotypes were considered together ( =0.028). However, in lung cancer patients administered a low dose of CPT-11, / variants were not significantly associated with severe neutropenia or delayed diarrhea. Furthermore, adult patients with the mutation were more likely to develop severe delayed diarrhea than did wild-type adults ( =0.013); however, the difference was not significant in elderly patients. No significant differences in tumor response were found among the different genotypes ( >0.05). Thus, age and tumor type influence our ability to predict adverse reactions based on gene polymorphisms in cancer patients. Further, gene polymorphisms are not correlated with the efficacy of CPT-11-based regimens.